HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Intestinal strongyloidiasis — Clinical Guidelines

Overview

Strongyloides stercoralis is a soil-transmitted helminth capable of persistent autoinfection, leading to chronic asymptomatic infection or potentially fulminant disseminated disease, especially in immunocompromised individuals 1 2.

Diagnosis

Clinical Presentation: Unexplained weight loss, gastrointestinal symptoms (vomiting, abdominal pain), and systemic signs (hypoxemia, shock) 1.

Endoscopy and Biopsy: Reveals characteristic histopathological findings of larvae in gastric, duodenal, or other tissues 1.

Laboratory Tests: Stool microscopy for larvae, though often negative in chronic or autoinfective cases; serological tests can be useful but specificity varies 2.

Immunocompromised Consideration: High index of suspicion in patients on immunosuppressive therapy 10.

Management

First-Line Treatment: Oral ivermectin (200 mcg/kg daily for 2-3 days, repeated after 2 weeks if necessary) 5.

Adjunctive Therapy: Albendazole (400 mg twice daily for 7-14 days) can be used in combination or as an alternative 5.

Parenteral Administration: Subcutaneous ivermectin (veterinary preparation) in cases refractory to oral therapy 5.

Corticosteroid Caution: Extreme caution with corticosteroid use due to risk of hyperinfection syndrome 4 8.

Special Populations

Immunocompromised Patients: Higher risk of disseminated disease; close monitoring and early aggressive treatment essential 1 4 10.

No Specific Guidance: Limited evidence directly addressing pregnancy, pediatrics, or elderly populations 2.

Key Recommendations

Maintain high suspicion for strongyloidiasis in endemic areas, especially among immunocompromised individuals presenting with unexplained gastrointestinal symptoms or systemic signs (Evidence: Moderate 1 10).

Initiate treatment with oral ivermectin as first-line therapy, considering adjunctive albendazole for refractory cases (Evidence: Moderate 5).

Avoid or use corticosteroids cautiously in patients with strongyloides infection due to risk of hyperinfection syndrome (Evidence: Weak 4 8).

References

1 Vinueza D, Collazos-Torres LA, Vallejo-Serna RA, Gómez-Gil BS, Quintero-Romero JM, Muñoz-Lombo JP. Strongyloides stercoralis: From chronic silent infection to fulminant catastrophe. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2026. link 2 Farthing M, Albonico M, Bisoffi Z, Bundy D, Buonfrate D, Chiodini P et al.. World Gastroenterology Organisation Global Guidelines: Management of Strongyloidiasis February 2018-Compact Version>. Journal of clinical gastroenterology 2020. link 3 Jouini R, Hedhli R, Khanchel F, Sabbah M, Trad D, Hlel I et al.. Anguillulosis: circumstances of infestation and evolution towards the malignant form. La Tunisie medicale 2019. link 4 Ghosh K, Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007. link 5 Chiodini PL, Reid AJ, Wiselka MJ, Firmin R, Foweraker J. Parenteral ivermectin in Strongyloides hyperinfection. Lancet (London, England) 2000. link02744-0) 6 Sane SY. Disseminated strongyloidiasis: report of two fatal cases. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 1989. link 7 Davidson RA. Strongyloides stercoralis infection in the ferret. The Journal of parasitology 1988. link 8 Dunlap NE, Shin MS, Polt SS, Ho KJ. Strongyloidiasis manifested as asthma. Southern medical journal 1984. link 9 Corsini AC. Strongyloidiasis and chronic urticaria. Postgraduate medical journal 1982. link 10 Bradley SL, Dines DE, Brewer NS. Disseminated Strongyloides stercoralis in an immunosuppressed host. Mayo Clinic proceedings 1978. link

Intestinal strongyloidiasis